Agency officials promise fast reviews of new treatments while vowing they will not be a “rubber stamp” for the industry. But patients with rare diseases view recent decisions as signs that the doors are closing on their options.Agency officials promise fast reviews of new treatments while vowing they will not be a “rubber stamp” for the industry. But patients with rare diseases view recent decisions as signs that the doors are closing on their options.
F.D.A. Faces Upset Over Denials of New Drugs
Date:
More like thisRelated
They Made it Through the 24 Hours That Rocked South Korea’s Markets
After explosive growth in recent months, the country’s benchmark...
Druski Talks About His Influences, Hollywood Ambitions and Timothée Chalamet
The comedian is building a galaxy of collaborators —...
Trump Wants a Quick Victory in Iran. But the War May Be Costly.
The opening days of the conflict are challenging the...
You’ve Never Seen Ants Like This Before
The Antscan database captures the tiny insects’ diversity and...